Outlook Therapeutics
Most recent annual filing: 2025-12-19
- ONS-5010/LYTENAVA corporate update2H 2026ONS-5010/LYTENAVA corporate update, 2H 2026, notable
- OTLK corporate updateSep 2026OTLK corporate update, Sep 2026, routine
- Atlas Sciences redemption right corporateSep 2026Atlas Sciences redemption right corporate, Sep 2026, routine
- Atlas Sciences Note corporate updateSep 16, 2026Atlas Sciences Note corporate update, Sep 16, 2026, routine
- OTLK corporate updateDec 31, 2026OTLK corporate update, Dec 31, 2026, routine
- Avondale March 2025 Note corporateDec 31, 2026Avondale March 2025 Note corporate, Dec 31, 2026, routine
- ONS-5010/LYTENAVA commercial launch2027ONS-5010/LYTENAVA commercial launch, 2027, notable
- OTLK corporate updateJun 16, 2027OTLK corporate update, Jun 16, 2027, routine
- Atlas March 2026 Note corporateJun 16, 2027Atlas March 2026 Note corporate, Jun 16, 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (3 active programs)
LYTENAVA
bevacizumab · ONS-5010Biotech Distilled coverage (9)
- 2026-08-19 UPDATE: Outlook Therapeutics (OTLK) - The 10-Q Nobody Wanted to Read 🔒 Paid
- 2026-08-14 UPDATE: Outlook Therapeutics (OTLK) - $55 Million, and the Market Sends the Invoice 🔒 Paid
- 2026-08-13 UPDATE: Outlook Therapeutics (OTLK) - The Bill for the Approval Comes Due 🔒 Paid
- 2026-07-24 UPDATE: Outlook Therapeutics (OTLK) — Six Trading Days to PDUFA, and the Supply Stack Just Got Named 🔒 Paid
- 2026-07-24 UPDATE: Outlook Therapeutics (OTLK) — Approved. Five Days Early. Now the Real Trade Starts. 🔒 Paid
- 2026-06-16 UPDATE: Outlook Therapeutics (OTLK) — The PDUFA Date Is July 29
- 2026-06-02 UPDATE: Outlook Therapeutics (OTLK) — The Clock Starts 🔒 Paid
- 2026-05-28 UPDATE: Outlook Therapeutics (OTLK) — The Anchor Doubles Down (and Reprices His Warrants) 🔒 Paid
- 2026-05-27 Outlook Therapeutics (OTLK) – Scientific Deep Dive for ONS-5010/LYTENAVA 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.